Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1398

Sort by

Sort Order Select

Journal Articles

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Jhansi Magisetty, Usha R. Pendurthi, Charles T. Esmon, L. Vijaya Mohan Rao

Blood (2020) 135 (25): 2211–2223.

https://doi.org/10.1182/blood.2019003824

Published: 2020

Includes: Supplemental data

Journal Articles

Activation of the Receptor Tyrosine Kinase (RET) By GDNF/GFRα1 Improves Cord Blood-Derived HSC in Vitro expansion and In Vivo engraftment

William Grey, PhD MSc, Rakhee Chauhan, PhD, Manuel Garcia-Albornoz, Hector Huerga Encabo, Neil McDonald, PhD, Dominique Bonnet, PhD

Blood (2019) 134 (Supplement_1): 1924.

https://doi.org/10.1182/blood-2019-121331

Published: 2019

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans

Amandeep Kaur, PhD, Katherine M Hannan, PhD, Samina Nazir, MSc, Kylee H Maclachlan, FRACP,FRCPA, Gretchen Poortinga, PhD, Si Ming Man, PhD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Ross D Hannan, PhD, Elizabeth E. Gardiner, PhD

Blood (2019) 134 (Supplement_1): 2360.

https://doi.org/10.1182/blood-2019-121713

Published: 2019

Journal Articles

Cell Competition and Microenvironment in the Development of Myeloproliferative Neoplasms

Melissa Castiglione, BS, Huichun Zhan, MD

Blood (2019) 134 (Supplement_1): 2485.

https://doi.org/10.1182/blood-2019-131074

Published: 2019

Journal Articles

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

Kishor Devalaraja-Narashimha, PhD DVM, Yan G Ni, PhD, Cong Huang, Ming-Dauh Wang, PhD, Umesh Chaudhari, MD, Srinivasa Prasad, PhD, Olivier Harari, MD PhD, Andrew J Rankin, PhD, Lori Morton, PhD, Jonathan Weyne, MD

Blood (2019) 134 (Supplement_1): 2278.

https://doi.org/10.1182/blood-2019-129865

Published: 2019

Journal Articles

Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)

Douglas W. Blayney, MD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2019) 134 (Supplement_1): 4861.

https://doi.org/10.1182/blood-2019-127227

Published: 2019

Journal Articles

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

Sarah A Lau-Braunhut, MD, Hannah Stone, Griffin Collins, MD, Sigbjørn Berentsen, MD PhD, Matt Zinter, MD, Benjamin Braun, MD PhD

Blood (2019) 134 (Supplement_1): 4798.

https://doi.org/10.1182/blood-2019-126365

Published: 2019

Journal Articles

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Bernice Oh, MBBS, MRCP, Shawn Lee, MD, Zelia Seeto, Germaine Liew, Bsc, Edwynn Chiew, MBBS, Zhi Wei Chen, Bsc, Yiong Huak Chan, PhD, Jing Jia Eng, Bsc, Koon Mian Foo, Bsc, Ching Mei Joyce Lam, MD, Ah Moy Tan, MD, Allen Eng Juh Yeoh, MD

Blood (2019) 134 (Supplement_1): 1307.

https://doi.org/10.1182/blood-2019-122098

Published: 2019

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naval G. Daver, MD, Pau Montesinos, MD PhD, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Nikolaos Papadantonakis, MDPhDMSc, Eric Deconinck, MD PhD, Harry P. Erba, MD PhD, Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, David A. Rizzieri, MD, Kendra L. Sweet, MD, Giovanni Martinelli, Corrado Tarella, MD, Elisabetta Todisco, MD PhD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, PhD, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 734.

https://doi.org/10.1182/blood-2019-128648

Published: 2019

Journal Articles

Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease

Baba PD Inusa, MD, Adlette Inati, MD, Philip Maes, MD, Jessie Githanga, MBChB, MMed, Miguel R. Abboud, MD, Maurizio Miano, Elena Cela, Videlis Nduba, Mohammad Niazi, Magnus Åstrand, Kevin Persson, Anders Rikard Berggren, MD PhD, Glenn Carlson, MD

Blood (2019) 134 (Supplement_1): 1005.

https://doi.org/10.1182/blood-2019-129855

Published: 2019

Journal Articles

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Tadeusz Robak, MD, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, MD PhD, Jacek Trelinski, Nichola Cooper, MD MRCP, Peter Kiessling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, Birgit Haier, James B. Bussel, MD, Stephen Jolles

Blood (2019) 134 (Supplement_1): 897.

https://doi.org/10.1182/blood-2019-129839

Published: 2019

Journal Articles

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Ian W. Flinn, MD PhD, Jason R. Westin, MD, Jonathon B. Cohen, MDMS, Luke P. Akard, MD, Samantha Jaglowski, MDMPH, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Veronika Bachanova, MD PhD

Blood (2019) 134 (Supplement_1): 1587.

https://doi.org/10.1182/blood-2019-125995

Published: 2019

Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 1584.

https://doi.org/10.1182/blood-2019-123949

Published: 2019

Journal Articles

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo , Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

Vinitha Mary Kuruvilla, MSc, Rebecca McCarthy, Qi Zhang, PhD, Callum M. Sloss, PhD, Patrick A. Zweidler-McKay, MD PhD, Angela Romanelli, PhD, Sharlene Adams, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1375.

https://doi.org/10.1182/blood-2019-124963

Published: 2019

Journal Articles

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Hind Al Azzawi, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 1379.

https://doi.org/10.1182/blood-2019-131348

Published: 2019

Journal Articles

Phase 1 Repeat Dosing with BIVV001: The First Investigational Factor VIII Product to Break through the Von Willebrand Factor-Imposed Half-Life Ceiling

Toshko Lissitchkov, Kara Rice, Suresh Katragadda, Annemieke Willemze, Craig Benson, Karin Knobe

Blood (2019) 134 (Supplement_1): 625.

https://doi.org/10.1182/blood-2019-122211

Published: 2019

Journal Articles

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Xiaorong Gu, PhD, Rita Tohme, PhD, Benjamin K. Tomlinson, MD, Lisa Durkin, Caroline Schuerger, Asmaa M Zidan, MB, BCh, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Ronald Sobecks, MD, Betty K. Hamilton, MD, Alan Lichtin, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 537.

https://doi.org/10.1182/blood-2019-125823

Published: 2019

Journal Articles

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

Blood (2019) 134 (Supplement_1): 610.

https://doi.org/10.1182/blood-2019-125968

Published: 2019

Journal Articles

Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects

Theodosia A. Kalfa, MD PhD, Frans A Kuypers, PhD, Marilyn J. Telen, MD, Punam Malik, MD, Diamantis G. Konstantinidis, PhD BSc, Jeremy H. Estepp, MD, Hyon J. Kim, MD PhD, Santosh L. Saraf, MD, Lindsey Wilson, Maria D Ribadeneira, PhD, Sanjeev Forsyth, Patricia Schroeder, Adam Drake, Olga Polyanskaya, Patrick Kelly, MD, Lukasz Biernat, MD

Blood (2019) 134 (Supplement_1): 616.

https://doi.org/10.1182/blood-2019-121889

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Activation of the Receptor Tyrosine Kinase (RET) By GDNF/GFRα1 Improves Cord Blood-Derived HSC in Vitro expansion and In Vivo engraftment

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans

Cell Competition and Microenvironment in the Development of Myeloproliferative Neoplasms

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo , Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

Phase 1 Repeat Dosing with BIVV001: The First Investigational Factor VIII Product to Break through the Von Willebrand Factor-Imposed Half-Life Ceiling

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only